Thalys Medical Technology Group Inc. Class A

Thalys Medical Technology Group Inc. Class A

SSSE:603716
14.28
CNY
-0.53
(-3.58%)
-0.84EPS
3.75BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.92
3.33
3.96
3.53
5.2
6.86
9.28
10.72
13.13
11.86
10.37
9.43
5.4
3.27
Basic EPS, GAAP
0.37
0.42
0.46
0.39
0.53
0.49
0.56
0.29
-0.25
-0.79
-0.82
-1.09
-1.04
-0.81
Free Cash Flow per Basic Share
-0.01
-0.01
0.04
-0.48
-1.01
-0.95
-0.01
-0.59
-0.98
-0.14
0.44
0.4
-0.22
- -
Dividend per Share
0.03
0.03
0.05
0.04
0.08
0.19
0.25
0.3
0.25
0.27
0.2
0.17
0.09
0.01
Book Value per Share
2.56
2.99
3.45
4.73
5.24
7.44
7.26
8.04
7.62
6.89
5.99
4.89
4.49
4.8
Tangible Book Value per Share
2.5
2.93
3.39
4.69
4.56
6.81
6.45
7.13
6.71
6.05
5.25
4.49
4.28
4.61
Basic Weighted Avg Shares
134
134
134
178
177
192
197
198
198
195
193
192
199
217
Sales/Revenue/Turnover
392
445
530
627
921
1,317
1,831
2,125
2,600
2,309
2,006
1,811
1,077
709
Operating Margin (%)
19.89
19.01
18.04
18.02
17.36
15.48
13.65
9.61
6.33
3.36
0.65
-1.26
-5.39
-11.94
Depreciation Expense
20
25
29
37
48
59
66
77
96
84
75
53
44
- -
Net Income, GAAP
49
57
61
69
94
94
110
58
-50
-154
-159
-209
-207
-176
Effective Tax Rate (%)
26.89
25.1
24.84
24.13
23.45
25.58
23.52
24.1
- -
- -
- -
- -
- -
- -
Profit Margin (%)
12.51
12.7
11.6
10.99
10.2
7.15
6.03
2.71
-1.9
-6.66
-7.9
-11.56
-19.25
-24.82
Working Capital
260
298
324
683
577
1,025
909
1,521
1,506
1,114
999
716
366
473
LT Debt
20
23
4
20
28
9
50
732
799
559
597
478
19
18
Total Equity
346
406
470
859
1,004
1,634
1,621
1,803
1,743
1,497
1,315
962
904
1,017
Return on Invested Capital (%)
13.35
13.03
11.69
8.98
9.09
6.5
6
3.12
- -
- -
- -
- -
- -
- -
Return on Capital (%)
13.6
13.24
11.9
8.72
7.55
5.17
4.76
2.68
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
15.42
15.23
14.29
10.57
10.56
7.65
7.32
3.67
-3.08
-10.37
-12.13
-19.51
-22.06
-17.96

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
355
236
214
LT Borrowings
3
3
3
LT Finance Leases
18
15
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
218
226
226
Market Capitalization
5,158
3,138
3,753

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,167
1,026
962
Cash, Cash Equivalents & STI
137
96
79
Accounts Receivable, Net
677
582
548
Inventories
199
189
180
Total Current Liabilities
725
541
489
Payables & Accruals
- -
- -
- -
ST Debt
355
236
214
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.03%
-12.48%
-5.98%
Free Cash Flow
226.22%
-121.93%
-156.91%
Net Income, GAAP
7.67%
11.74%
-0.93%
Sales/Revenue/Turnover
11.11%
-10.45%
-40.52%
Total Cash Common Dividend
20.81%
-19.3%
-41.45%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
485
491
444
391
1,811
2025
287
296
- -
220
1,077
2026
182
161
147
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
-0.04
-0.27
-0.82
-1.09
2025
-0.07
-0.22
- -
-0.58
-1.04
2026
-0.08
-0.14
-0.04
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.25
0.08
-0.04
0.17
2025
0.02
0.03
- -
-0.03
0.09
2026
0.01
0.02
0.01
- -
- -

Company Description

CEO
Zheng Wang
Full Time Employees
1,045
Sector
Distribution services
Industry
Medical distributors
Address
1310 Jinshan Avenue Wuhan HB China 430040
IPO Date
Oct 31, 2016
Business
Thalys Medical Technology Group Corporation (603716.SS) provides intensive medical inspection operation services, integrated IVD laboratory solutions, and medical consumables management in China. The company offers automated immunofluorescence analyzers, automatic coagulation analyzers, coagulation reagents, blood gas detection analyzers, automatic fluorescence immunoassay analyzers; intensive distribution and simple sales of in vitro diagnostic products; cooperative construction of regional testing centers; SPD services for medical consumables; and LIS/IoT solutions with full-process supply chain management. Founded in 2004 and headquartered in Wuhan, China, it primarily serves hospitals and medical institutions across the country through one-stop medical business intensification. In September 2020, the company changed its name from Thalys Medical Technology Inc. to Thalys Medical Technology Group Inc.; in September 2025, it agreed to acquire a controlling stake in an associate for CNY 70 million; it also engages in partnerships such as with Genetic Analysis AS for product launches and collaborations for thrombosis/hemostasis diagnostics.